Bio tech company updates — 10/28/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korea's biotech sector is experiencing a surge in activity and export growth as BioPlus-Interphex Korea 2026 (BIX 2026) opens in Seoul, gathering over 300 companies. Recent data reveals record bio-health exports of $24.8 billion, while Samsung Biologics launched a new antibody platform and seven startups pursue KOSDAQ listings.
Key Findings
- Record Exports: South Korea’s bio-health exports reached a record $24.75 billion in the first nine months of 2026, a 19.4% increase year-over-year, with annual shipments projected to exceed $30 billion.
- BIX 2026 Opens: The annual BioPlus-Interphex Korea 2026 (BIX 2026) convention opened at COEX in Seoul on October 28, bringing together approximately 300 domestic and international biotech companies to discuss drug development and commercialization.
- Samsung Biologics Platform Launch: Samsung Biologics unveiled a custom Chemistry, Manufacturing, and Controls (CMC) platform for bispecific antibodies, aiming to reduce the cell line-to-IND timeline from 13 months to 9.5 months.
- Startup Listings: Seven Korean biotech startups, led by CEOs in their 30s and 40s, are pursuing KOSDAQ listings utilizing Antibody-Drug Conjugate (ADC), multispecific antibody, and AI technologies.
Details
BIX 2026: Industry Leaders Convene in Seoul
The biotech industry's largest annual event, BIX 2026, began on October 28 at COEX in Seoul, focusing on next-generation drug development and global commercialization strategies. The event features participation from global pharma and biotech entities, including Samsung Bioepis and Merck.
During the opening, the head of the Korea Biotechnology Industry Organization (KBIO) urged the government for tangible support for drug developers, noting that current technologies lack originality. On-site demonstrations highlighted the practical applications of biotech, such as a glove at the Samsung Bioepis booth simulating the physical difficulties of rheumatoid arthritis.
Export Growth and Corporate Innovations
South Korea's bio-health sector continues to demonstrate robust growth, with exports hitting a record high of $24.75 billion through September 2026. This growth is driven by a 31% surge in cosmetics and rising biopharmaceutical demand in Europe.
On the corporate front, Samsung Biologics announced a new custom CMC capability for bispecific antibodies on October 28, designed to accelerate development timelines. Meanwhile, the KOSDAQ market is seeing an influx of new entrants, with seven startups specializing in ADC, multispecific antibodies, and AI-driven drug discovery seeking listings.
Sources
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
